BIORCHESTRA Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program 2023-07-17 21:28
BIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference 2023-06-01 20:00
BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States 2023-04-25 20:00
BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program 2023-04-24 20:00
BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer 2023-04-05 20:00
BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies 2023-03-27 20:00
BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events 2023-03-08 22:47
BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy 2022-12-15 21:00
BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston 2022-11-08 15:59
BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston 2022-11-08 15:30
BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology 2022-08-23 20:00
BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention 2022-06-09 20:30
BIORCHESTRA Participated in Formulation and Delivery 2022-05-12 21:00
BIORCHESTRA Announces 45 Million USD Series C Fundraising 2022-02-23 11:26
BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics 2022-01-05 08:07
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston 2021-11-08 22:59
BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA 2021-09-23 20:00
1